Actithera significantly strengthens leadership team and Board as Company advances towards clinical development
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Actithera Names Steven Kelly CEO as Radiopharmaceutical Pipeline Nears Clinical Development
Actithera has appointed Steven Kelly as chief executive officer and a member of its board as the radiopharmaceutical biotech company prepares to move its lead fibroblast activation protein-targeted radioligand therapy into clinical development. The Oslo, Norway, and Cambridge, Massachusetts-based company also named Briggs Morrison chair of the board and John Crowley an independent director. The leadership changes come as Actithera shifts from bu…
Actithera significantly strengthens leadership team and Board as Company advances towards clinical development
Steven Kelly appointed Chief Executive Officer to lead Actithera through clinical development and continued pipeline expansion Briggs Morrison appointed Chair of the Board, bringing extensive biotech leadership and oncology drug development expertise John Crowley appointed Independent Director, adding proven strategic, financial and capital markets leadership Oslo, Norway and Cambridge, Massachusetts — 10 September 2026
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
